CUR - ニュ―ラルステム (Neuralstem Inc.) ニュ―ラルステム



symbol CUR
会社名 Neuralstem Inc (ニュ―ラルステム)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Neuralstem Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company''s technology allows the commercial-scale production of multiple types of central nervous system stem cells which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company''s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS) chronic spinal cord injury and motor deficits due to ischemic stroke.   ニュ―ラルステムは米国のバイオ医薬品メ―カ―。ヒト神経幹細胞の特許技術を保有し、中枢神経系疾患の治療に注力する。筋萎縮性側索硬化症、脊髄損傷、虚血性脳梗塞、多発性硬化症、アルツハイマ―病などの細胞治療に取り組む。また、新しいニュ―ロンの成長を刺激する小分子化合物の特許を取得、うつ病および認知障害用治療薬を開発する。本社はメリ―ランド州。   Neuralstem, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.
本社所在地 20271 Goldenrod Lane Germantown MD 20876 USA
代表者氏名 William Clyde Oldaker ウィリアム・クライド・オスターダー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 301-366-4841
設立年月日 1997年
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 33人
EBITDA EBITDA(百万ドル) -9.00590
終値(lastsale) 1.115
時価総額(marketcap) 16903415.61
時価総額 時価総額(百万ドル) 15.46321
売上高 売上高(百万ドル) 0.51000
企業価値(EV) 企業価値(EV)(百万ドル) 8.38038
当期純利益 当期純利益(百万ドル) -6.22355
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Neuralstem Inc. revenues increased from $5K to $255K. Net loss decreased 77% to $2.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Gain from change in fair value of deriva increase from $3.1M (expense) to $1.6M (income) Other Non Operating I/E decrease of 99% to $6K (expense).


 関連キーワード  (医薬品 米国株 ニュ―ラルステム CUR Neuralstem Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)